

Bruce J Trock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8870698/publications.pdf>

Version: 2024-02-01

209
papers

13,601
citations

27035

58
h-index

26792

111
g-index

212
all docs

212
docs citations

212
times ranked

14246
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2022, 5, 113-117.	2.6	30
2	The Movember Global Action Plan 1 (GAP1): Unique Prostate Cancer Tissue Microarray Resource. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 715-727.	1.1	0
3	Urinary MyProstateScore (MPS) to Rule out Clinically-Significant Cancer in Men with Equivocal (PI-RADS 3) Multiparametric MRI: Addressing an Unmet Clinical Need. <i>Urology</i> , 2022, 164, 184-190.	0.5	8
4	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	1.2	6
5	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022, 40, 19-26.	0.2	7
6	Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. <i>European Urology Open Science</i> , 2022, 41, 126-133.	0.2	5
7	Personalised biopsy schedules based on risk of Gleason upgrading for patients with low-risk prostate cancer on active surveillance. <i>BJU International</i> , 2021, 127, 96-107.	1.3	15
8	Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort. <i>European Radiology</i> , 2021, 31, 1644-1655.	2.3	37
9	Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 320-329.	3.2	46
10	A comparative study of PCS and PAM50 prostate cancer classification schemes. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 733-742.	2.0	14
11	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 247-247.	0.8	0
12	Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0245530.	1.1	21
13	Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
14	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	2.0	10
15	C1Q&agraronF&agraronrelated peptide 8 (CTRP8) in human prostate cancer. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
16	Chronic pain associated with penile prostheses may persist despite revision or explantation. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.3	3
17	GSTP1 positive prostatic adenocarcinomas are more common in Black than White men in the United States. <i>PLoS ONE</i> , 2021, 16, e0241934.	1.1	14
18	Volume-outcome relationships for kidney cancer may be driven by disparities and patient risk. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 439.e1-439.e8.	0.8	1

#	ARTICLE	IF	CITATIONS
19	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021, 4, e2115312.	2.8	12
20	Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death. <i>Journal of Clinical Oncology</i> , 2021, 39, 2284-2293.	0.8	54
21	Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies. <i>Journal of Urology</i> , 2021, 206, 623-629.	0.2	4
22	External validation of the priapism impact profile in a Jamaican cohort of patients with sickle cell disease. <i>PLoS ONE</i> , 2021, 16, e0258560.	1.1	2
23	Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. <i>European Urology Open Science</i> , 2021, 34, 47-54.	0.2	3
24	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomographyâ€Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2138550.	2.8	18
25	Adherence to Active Surveillance Protocols for Low-risk Prostate Cancer: Results of the Movember Foundationâ€™s Global Action Plan Prostate Cancer Active Surveillance Initiative. <i>European Urology Oncology</i> , 2020, 3, 80-91.	2.6	24
26	A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 184-193.	2.0	32
27	Prospective Comparison of PET Imaging with PSMA-Targeted ¹⁸ F-DCFPyL Versus Na ¹⁸ F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 183-188.	2.8	27
28	Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. <i>Cancer</i> , 2020, 126, 583-592.	2.0	9
29	Urinary Incontinence and Pelvic Organ Prolapse Knowledge, Care-Seeking, and Embarrassment in Women Planning Bariatric Surgery: A Cross-sectional Study. <i>Female Pelvic Medicine and Reconstructive Surgery</i> , 2020, 26, 276-280.	0.6	4
30	The incidence, predictors, and survival of disappearing small renal masses on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 42.e1-42.e6.	0.8	3
31	Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4869-4881.	3.2	18
32	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	0.9	22
33	Five-year Outcomes of Magnetic Resonance Imagingâ€based Active Surveillance for Prostate Cancer: A Large Cohort Study. <i>European Urology</i> , 2020, 78, 443-451.	0.9	94
34	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 646-653.	2.0	17
35	Reducing preoperative blood orders and costs for radical prostatectomy. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 219-226.	0.6	1
36	Predictors of a successful primary bladder closure in cloacal exstrophy: A multivariable analysis. <i>Journal of Pediatric Surgery</i> , 2019, 54, 491-494.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Comparative effectiveness of management options for patients with small renal masses: a prospective cohort study. <i>BJU International</i> , 2019, 123, 42-50.	1.3	65
38	Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. <i>European Urology</i> , 2019, 76, 693-702.	0.9	18
39	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 470-475.e1.	0.9	26
40	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-14.	1.5	23
41	The dual-staged pathway for closure in cloacal exstrophy: Successful evolution in collaborative surgical practice. <i>Journal of Pediatric Surgery</i> , 2019, 54, 1761-1765.	0.8	6
42	Meta-analysis of randomized controlled trials that assess the efficacy of low-intensity shockwave therapy for the treatment of erectile dysfunction. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721983836.	0.9	34
43	Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. <i>European Urology Oncology</i> , 2019, 2, 333-336.	2.6	8
44	Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 399-405.	2.0	53
45	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 584-590.	1.1	8
46	Effect of Preanalytic Variables on an Automated PTEN Immunohistochemistry Assay for Prostate Cancer. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 338-348.	1.2	7
47	Distinct transcriptional repertoire of the androgen receptor in ETS fusion-negative prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 292-302.	2.0	10
48	Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium. <i>European Urology</i> , 2019, 75, 523-531.	0.9	58
49	PTEN status assessment in the Johns Hopkins active surveillance cohort. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 176-181.	2.0	13
50	Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>European Urology</i> , 2018, 73, 168-175.	0.9	53
51	Growth Kinetics of Small Renal Masses on Active Surveillance: Variability and Results from the DISSRM Registry. <i>Journal of Urology</i> , 2018, 199, 641-648.	0.2	81
52	Prostate Specific Antigen Testing after Radical Prostatectomy—Can We Stop at 20 Years?. <i>Journal of Urology</i> , 2018, 199, 114-119.	0.2	7
53	Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	1.5	29
54	Estimating and comparing cancer progression risks under varying surveillance protocols. <i>Annals of Applied Statistics</i> , 2018, 12, 1773-1795.	0.5	8

#	ARTICLE	IF	CITATIONS
55	Development and Validation of a Prostate Cancer Genomic Signature that Predicts Early ADT Treatment Response Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2018, 24, 3908-3916.	3.2	24
56	Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2117-2125.	1.2	19
57	Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. <i>Annals of Internal Medicine</i> , 2018, 168, 1.	2.0	33
58	Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. <i>Eur Urol</i> 2017;71:907-12. <i>European Urology</i> , 2017, 72, e11-e12.	0.9	1
59	Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men. <i>Urology</i> , 2017, 104, 143-149.	0.5	4
60	Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens. <i>European Urology</i> , 2017, 72, 845-852.	0.9	79
61	A Framework for Treatment Decision Making at Prostate Cancer Recurrence. <i>Medical Decision Making</i> , 2017, 37, 905-913.	1.2	6
62	Editorial Comment. <i>Urology</i> , 2017, 107, 73-74.	0.5	0
63	Reply to Erfan Ayubi and Saied Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2017.03.036 . <i>Methodological Issues. European Urology</i> , 2017, 72, e158-e159.	0.9	0
64	Barriers to radiotherapy access at the University College Hospital in Ibadan, Nigeria. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 1-5.	0.9	13
65	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2017, 197, 1060-1067.	0.2	10
66	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. <i>European Urology</i> , 2017, 71, 907-912.	0.9	44
67	Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy. <i>European Urology</i> , 2017, 71, 697-700.	0.9	65
68	Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential. <i>Journal of Urology</i> , 2017, 197, 122-128.	0.2	33
69	Risk prediction tool for grade reclassification in men with favourable-risk prostate cancer on active surveillance. <i>BJU International</i> , 2017, 120, 25-31.	1.3	29
70	Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. <i>European Urology</i> , 2017, 71, 274-280.	0.9	11
71	Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. <i>BJU International</i> , 2017, 119, 676-683.	1.3	86
72	Rapid Loss of RNA Detection by In Situ Hybridization in Stored Tissue Blocks and Preservation by Cold Storage of Unstained Slides. <i>American Journal of Clinical Pathology</i> , 2017, 148, 398-415.	0.4	52

#	ARTICLE	IF	CITATIONS
73	Prostate MRI prior to radical prostatectomy: effects on nerve sparing and pathological margin status. Research and Reports in Urology, 2017, Volume 9, 55-63.	0.6	11
74	Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. Journal of Clinical Oncology, 2017, 35, 1991-1998.	0.8	176
75	PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5075-5075.	0.8	2
76	Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.. Journal of Clinical Oncology, 2017, 2017, 4-4.	0.8	1
77	Intermediate-term outcomes from the DISSRM registry: A prospective analysis of active surveillance in patients with small renal masses.. Journal of Clinical Oncology, 2017, 35, 430-430.	0.8	7
78	Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget, 2017, 8, 15651-15662.	0.8	20
79	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5062-5062.	0.8	1
80	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.2	38
81	A Prospective, Comparative Study of Quality of Life among Patients with Small Renal Masses Choosing Active Surveillance and Primary Intervention. Journal of Urology, 2016, 196, 1356-1362.	0.2	51
82	Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical Cystectomy. Annals of Surgical Oncology, 2016, 23, 2715-2722.	0.7	34
83	PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology, 2016, 29, 764-771.	2.9	53
84	Molecular Triage of Premalignant Lesions in Liquid-Based Cervical Cytology and Circulating Cell-Free DNA from Urine, Using a Panel of Methylated Human Papilloma Virus and Host Genes. Cancer Prevention Research, 2016, 9, 915-924.	0.7	29
85	Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting. Molecular Cancer Therapeutics, 2016, 15, 2541-2550.	1.9	9
86	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 496-504.	0.9	23
87	Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery. European Urology, 2016, 69, 576-581.	0.9	42
88	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. European Urology, 2016, 69, 157-165.	0.9	206
89	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. PLoS ONE, 2016, 11, e0146189.	1.1	13
90	CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Transactions of the American Clinical and Climatological Association, 2016, 127, 313-327.	0.9	1

#	ARTICLE	IF	CITATIONS
91	Nightly sildenafil use after radical prostatectomy has adverse effects on urinary convalescence: Results from a randomized trial of nightly vs on-demand dosing regimens. Canadian Urological Association Journal, 2015, 9, 414.	0.3	7
92	Five-year Analysis of a Multi-institutional Prospective Clinical Trial of Delayed Intervention and Surveillance for Small Renal Masses: The DISSRM Registry. European Urology, 2015, 68, 408-415.	0.9	282
93	Nanowire Analysis of Cancer-Testis Antigens as Biomarkers of Aggressive Prostate Cancer. Urology, 2015, 85, 704.e1-704.e7.	0.5	24
94	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. European Urology, 2015, 67, 342-346.	0.9	47
95	Fluoroquinolone Resistance in the Rectal Carriage of Men in an Active Surveillance Cohort: Longitudinal Analysis. Journal of Urology, 2015, 193, 552-556.	0.2	29
96	Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols. BJU International, 2015, 115, 216-222.	1.3	25
97	Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?. Cancer, 2015, 121, 1414-1421.	2.0	12
98	Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology, 2015, 68, 555-567.	0.9	125
99	Variability in Medicare Utilization and Payment Among Urologists. Urology, 2015, 85, 1045-1051.	0.5	36
100	Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: A multi-institutional analysis. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 112.e9-112.e14.	0.8	36
101	Predictors of Adverse Pathology in Men Undergoing Radical Prostatectomy Following Initial Active Surveillance. Urology, 2015, 86, 991-997.	0.5	13
102	Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer. Journal of Clinical Oncology, 2015, 33, 3379-3385.	0.8	454
103	Reclassification Rates Are Higher Among African American Men Than Caucasians on Active Surveillance. Urology, 2015, 85, 155-160.	0.5	64
104	Magnetic Resonance "invisible Versus Magnetic Resonance "visible Prostate Cancer in Active Surveillance: A Preliminary Report on Disease Outcomes. Urology, 2015, 85, 147-154.	0.5	50
105	Modeling grade progression in an active surveillance study. Statistics in Medicine, 2014, 33, 930-939.	0.8	41
106	Biobanking of derivatives from radical retropubic and robot-assisted laparoscopic prostatectomy tissues as part of the prostate cancer biorepository network. Prostate, 2014, 74, 61-69.	1.2	16
107	Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Current Opinion in Urology, 2014, 24, 293-302.	0.9	20
108	Overdetection of Recurrence after Radical Prostatectomy: Estimates Based on Patient and Tumor Characteristics. Clinical Cancer Research, 2014, 20, 5302-5310.	3.2	19

#	ARTICLE	IF	CITATIONS
109	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. <i>Journal of Urology</i> , 2014, 192, 1081-1087.	0.2	196
110	Adjuvant Radiation Following Radical Prostatectomy: What Are the Known Unknowns?. <i>European Urology</i> , 2014, 66, 251-252.	0.9	4
111	Editorial Comment. <i>Urology</i> , 2014, 84, 1079.	0.5	0
112	Biopsy Criteria for Determining Appropriateness for Active Surveillance in the Modern Era. <i>Urology</i> , 2014, 83, 869-874.	0.5	95
113	Predicting the Risk of Non-organ-confined Prostate Cancer When Perineural Invasion Is Found on Biopsy. <i>Urology</i> , 2014, 83, 1117-1121.	0.5	9
114	Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: The Johns Hopkins Hospital 30-year experience. <i>Prostate</i> , 2013, 73, 1673-1680.	1.2	51
115	Urinary Outcomes Are Significantly Affected by Nerve Sparing Quality During Radical Prostatectomy. <i>Urology</i> , 2013, 82, 1348-1354.	0.5	34
116	Multiphasic Enhancement Patterns of Small Renal Masses (≤ 4 cm) on Preoperative Computed Tomography: Utility for Distinguishing Subtypes of Renal Cell Carcinoma, Angiomyolipoma, and Oncocytoma. <i>Urology</i> , 2013, 81, 1265-1272.	0.5	107
117	Laparoscopic and Robotic Radical Prostatectomy Outcomes in Obese and Extremely Obese Men. <i>Urology</i> , 2013, 82, 600-605.	0.5	36
118	Active surveillance for low-risk prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 295-302.	2.0	46
119	Comparison of Biochemical Recurrence-Free Survival Between Periprostatic and Pelvic Lymph Node Metastases of Prostate Cancer. <i>International Journal of Surgical Pathology</i> , 2013, 21, 352-357.	0.4	5
120	Nightly vs on-demand sildenafil for penile rehabilitation after minimally invasive nerve-sparing radical prostatectomy: results of a randomized double-blind trial with placebo. <i>BJU International</i> , 2013, 112, 844-851.	1.3	88
121	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4294-4296.	0.8	162
122	Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2012, 18, 5471-5478.	3.2	52
123	Treatment decision-making for localized prostate cancer: What younger men choose and why. <i>Prostate</i> , 2012, 72, 58-64.	1.2	93
124	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. <i>BJU International</i> , 2012, 109, 32-39.	1.3	221
125	Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary Grades. <i>European Urology</i> , 2012, 61, 1019-1024.	0.9	550
126	Comparison of outcomes between pure laparoscopic vs robot-assisted laparoscopic radical prostatectomy: a study of comparative effectiveness based upon validated quality of life outcomes. <i>BJU International</i> , 2012, 109, 898-905.	1.3	69

#	ARTICLE	IF	CITATIONS
127	Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. <i>BJU International</i> , 2012, 110, 56-62.	1.3	88
128	Effect of treatment with 5 α -reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. <i>BJU International</i> , 2012, 110, 651-657.	1.3	34
129	Impact of surgical margin status on prostate-cancer-specific mortality. <i>BJU International</i> , 2012, 110, 1684-1689.	1.3	82
130	Medical Comorbidities Associated With Pediatric Kidney Stone Disease. <i>Urology</i> , 2011, 77, 195-199.	0.5	37
131	Tandem-robot Assisted Laparoscopic Radical Prostatectomy to Improve the Neurovascular Bundle Visualization: A Feasibility Study. <i>Urology</i> , 2011, 77, 502-506.	0.5	64
132	Incidence and Risk Factors for Inguinal and Incisional Hernia After Laparoscopic Radical Prostatectomy. <i>Urology</i> , 2011, 77, 957-962.	0.5	30
133	Application of metabolomics to prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 572-581.	0.8	104
134	Should Intervening Benign Tissue Be Included in the Measurement of Discontinuous Foci of Cancer on Prostate Needle Biopsy? Correlation With Radical Prostatectomy Findings. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1351-1355.	2.1	66
135	Re: Randomised Prostate Cancer Screening Trial: 20 Year Follow-up. <i>European Urology</i> , 2011, 60, 1306-1307.	0.9	2
136	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 2185-2190.	0.8	545
137	Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 228-237.	2.3	29
138	Epidemiologic insights into pediatric kidney stone disease. <i>Urological Research</i> , 2010, 38, 453-457.	1.5	59
139	A Targeted Proteomics Approach for Biomarker Discovery Using Bilateral Matched Nipple Aspiration Fluids. <i>Clinical Proteomics</i> , 2010, 6, 57-64.	1.1	0
140	A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. <i>Breast Cancer Research and Treatment</i> , 2010, 123, 73-86.	1.1	16
141	Interpretation of the prostate-specific antigen history in assessing life-threatening prostate cancer. <i>BJU International</i> , 2010, 106, 1284-1292.	1.3	8
142	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. <i>BJU International</i> , 2010, 106, 1612-1617.	1.3	13
143	What Are the Outcomes of Radical Prostatectomy for High-risk Prostate Cancer?. <i>Urology</i> , 2010, 76, 710-714.	0.5	119
144	Novel biomarkers for risk of prostate cancer: Results from a case-control study. <i>Prostate</i> , 2009, 69, 41-48.	1.2	47

#	ARTICLE	IF	CITATIONS
145	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. <i>Prostate</i> , 2009, 69, 1195-1205.	1.2	93
146	Pathologic Findings in Patients with Ureteropelvic Junction Obstruction and Crossing Vessels. <i>Urology</i> , 2009, 73, 716-719.	0.5	45
147	Sex Prevalence of Pediatric Kidney Stone Disease in the United States: An Epidemiologic Investigation. <i>Urology</i> , 2009, 74, 104-107.	0.5	158
148	Tertiary Gleason Patterns and Biochemical Recurrence After Prostatectomy: Proposal for a Modified Gleason Scoring System. <i>Journal of Urology</i> , 2009, 182, 1364-1370.	0.2	87
149	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. <i>Prostate</i> , 2008, 68, 1257-1262.	1.2	47
150	Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. <i>Nature Genetics</i> , 2008, 40, 1153-1155.	9.4	158
151	Natural History of Pathologically Organ-Confined (pT2), Gleason Score 6 or Less, Prostate Cancer After Radical Prostatectomy. <i>Urology</i> , 2008, 72, 172-176.	0.5	73
152	The Effect of Ureteral Stent Placement on Post-ureteroscopy Complications: A Meta-analysis. <i>Urology</i> , 2008, 71, 796-800.	0.5	54
153	Impact of Body Mass Index on Biochemical Recurrence Rates After Radical Prostatectomy: An Analysis Utilizing Propensity Score Matching. <i>Urology</i> , 2008, 72, 1246-1251.	0.5	48
154	Elective Laparoscopic Partial Nephrectomy in Patients with Tumors >4 cm. <i>Urology</i> , 2008, 72, 580-583.	0.5	53
155	A clinician's guide to statistical methods in urologic oncology. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 299.	0.8	0
156	Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5819-5824.	3.2	61
157	Prostate Cancer-Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2760.	3.8	586
158	National Institutes of Health State-of-the-Science Conference Statement: Prevention of Fecal and Urinary Incontinence in Adults. <i>Annals of Internal Medicine</i> , 2008, 148, 449.	2.0	237
159	Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1836-1844.	3.0	235
160	Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1525-1533.	3.0	126
161	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 5361-5367.	3.2	82
162	Oncologic Outcomes of Extravesical Stapling of Distal Ureter in Laparoscopic Nephroureterectomy. <i>Journal of Endourology</i> , 2007, 21, 1025-1028.	1.1	26

#	ARTICLE	IF	CITATIONS
163	Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005. <i>Urology</i> , 2007, 69, 1095-1101.	0.5	410
164	Comparison of Open and Laparoscopic Radical Prostatectomy Outcomes from a Surgeon's Early Experience. <i>Urology</i> , 2007, 70, 667-671.	0.5	12
165	Recurrence-Free Survival After Radical Cystectomy of Patients Downstaged by Transurethral Resection. <i>Urology</i> , 2007, 70, 1091-1095.	0.5	15
166	Complexed prostate-specific antigen for the diagnosis of biochemical recurrence after radical prostatectomy. <i>BJU International</i> , 2007, 99, 758-761.	1.3	10
167	Meta-Analysis of Soy Intake and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2006, 98, 459-471.	3.0	417
168	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. <i>Urology</i> , 2006, 67, 115-119.	0.5	34
169	Lipophilic Statins Merit Additional Study for Breast Cancer Chemoprevention. <i>Journal of Clinical Oncology</i> , 2006, 24, 2128-2129.	0.8	16
170	Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of Curability. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1521-1527.	3.0	287
171	Delayed Versus Immediate Surgical Intervention and Prostate Cancer Outcome. <i>Journal of the National Cancer Institute</i> , 2006, 98, 355-357.	3.0	200
172	Intraoperative Conversion of Laparoscopic Partial Nephrectomy. <i>Journal of Endourology</i> , 2006, 20, 205-208.	1.1	23
173	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4037-4043.	3.2	198
174	Racial Differences in Prognostic Value of Adult Height for Biochemical Progression Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 7735-7742.	3.2	1
175	Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. <i>Journal of Clinical Investigation</i> , 2005, 115, 1163-1176.	3.9	338
176	A Pilot Surrogate End Point Biomarker Trial of Perillyl Alcohol in Breast Neoplasia. <i>Clinical Cancer Research</i> , 2004, 10, 7583-7591.	3.2	20
177	A Pilot Study to Establish a Clinical Model to Perform Phase II Studies of Breast Cancer Chemopreventive Agents in Women at High Risk with Biomarkers as Surrogate Endpoints for Activity. <i>Clinical Cancer Research</i> , 2004, 10, 8332-8340.	3.2	10
178	Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels. <i>Cancer</i> , 2004, 101, 748-753.	2.0	24
179	Evaluation of water jet morcellation as an alternative to hand morcellation of renal tissue ablation during laparoscopic nephrectomy: an in vitro study. <i>Urology</i> , 2004, 63, 796-799.	0.5	4
180	Long-Term pooled analysis of multicenter studies of cooled thermotherapy for benign prostatic hyperplasia: results at three months through four years. <i>Urology</i> , 2004, 63, 716-721.	0.5	22

#	ARTICLE	IF	CITATIONS
181	Laparoscopic Live Donor Nephrectomy. <i>Annals of Surgery</i> , 2004, 240, 358-363.	2.1	133
182	129: The Effect of Hospital Volume on Cancer Control After Radical Prostatectomy. <i>Journal of Urology</i> , 2004, 171, 34-34.	0.2	0
183	Acceptability of Diagnostic Tests for Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 199-206.	1.1	33
184	Cadmium mimics the in vivo effects of estrogen in the uterus and mammary gland. <i>Nature Medicine</i> , 2003, 9, 1081-1084.	15.2	498
185	Laparoscopic adult donor nephrectomy for pediatric renal transplantation. <i>Urology</i> , 2003, 61, 320-322.	0.5	24
186	Impact of renal artery multiplicity on outcomes of renal donors and recipients in laparoscopic donor nephrectomy. <i>Urology</i> , 2003, 61, 323-327.	0.5	115
187	Prevalence of Plasmodium falciparum infection in pregnant Cameroonian women.. <i>American Journal of Tropical Medicine and Hygiene</i> , 2002, 67, 566-570.	0.6	23
188	Prognostic significance of preoperative molecular serum analysis in renal cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1878-81.	3.2	23
189	Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials. <i>Urology</i> , 2001, 57, 241-247.	0.5	12
190	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. <i>Urology</i> , 2001, 58, 746-751.	0.5	71
191	Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer. <i>Disease Markers</i> , 2001, 17, 301-307.	0.6	278
192	Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?. <i>Breast Cancer Research and Treatment</i> , 1998, 52, 305-319.	1.1	180
193	Serendipity in Diagnostic Imaging: Magnetic Resonance Imaging of the Breast. <i>Journal of the National Cancer Institute</i> , 1998, 90, 1792-1800.	3.0	19
194	Breast cancer in African American women: Epidemiology and tumor biology. <i>Breast Cancer Research and Treatment</i> , 1996, 40, 11-24.	1.1	59
195	The Optimal Temporal Window for CT of the Liver Using a Timeâ€”Density Analysis. <i>Journal of Computer Assisted Tomography</i> , 1995, 19, 73-79.	0.5	22
196	Management of primary central nervous system lymphoma for the patient with acquired immunodeficiency syndrome. <i>Confronting a clinical catch-22</i> . <i>Cancer</i> , 1995, 76, 163-166.	2.0	11
197	Phase II study of oral etoposide for patients with advanced breast cancer. <i>Cancer</i> , 1995, 76, 2485-2490.	2.0	24
198	Application of biological markers in cancer environmental epidemiology. <i>Toxicology</i> , 1995, 101, 93-98.	2.0	2

#	ARTICLE	IF	CITATIONS
199	p53 is overexpressed in fifty percent of pre-invasive lesions of head and neck epithelium. Carcinogenesis, 1994, 15, 2269-2274.	1.3	57
200	Natural history of dysplastic nevi. Journal of the American Academy of Dermatology, 1993, 29, 51-57.	0.6	105
201	A Cohort Study of Melanoma in Patients with Dysplastic Nevi. Journal of Investigative Dermatology, 1993, 100, S346-S349.	0.3	59
202	The logistic modeling of sensitivity, specificity, and predictive value of a diagnostic test. Journal of Clinical Epidemiology, 1992, 45, 1-7.	2.4	147
203	Dr Diamond's "clinical epistemology of sensitivity and specificity". Journal of Clinical Epidemiology, 1992, 45, 15-16.	2.4	2
204	Regression Methods for Estimating Attributable Risk in Population-based Case-Control Studies: A Comparison of Additive and Multiplicative Models. American Journal of Epidemiology, 1991, 133, 305-313.	1.6	34
205	Randomized trials of adjuvant radiation therapy for rectal carcinoma. Diseases of the Colon and Rectum, 1990, 33, 335-343.	0.7	13
206	Factors associated with repeat adherence to breast cancer screening. Preventive Medicine, 1990, 19, 279-290.	1.6	444
207	Adherence to colorectal cancer screening in an HMO population. Preventive Medicine, 1990, 19, 502-514.	1.6	93
208	Interactions and public health decisions. Journal of Clinical Epidemiology, 1988, 41, 207-209.	2.4	2
209	CRITICISM AND THE GROWTH OF EPIDEMIOLOGIC KNOWLEDGE. (RE: "POPPERIAN REFUTATION IN) Tj ETQq1 1.0.784314 rgBT /Ove	1.6	10